SGN 35C
Alternative Names: PF-08046044; SGN-35CLatest Information Update: 03 May 2024
Price :
$50 *
At a glance
- Originator Seagen
- Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunotoxins
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma
Most Recent Events
- 23 Apr 2024 Phase-I clinical trials in Lymphoma (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT06254495)
- 12 Feb 2024 Seagen plans a phase I trial for Cancer (Late-stage disease, Second-line therapy or greater) (IV) in May 2024 (NCT06254495)
- 14 Dec 2023 Seagen has been acquired by Pfizer